Corporate News tagged:
Drug Discovery (2)
Nov 13, 2019
Lantern Pharma Selects REPROCELL Inc., for Drug Screening and Biomarker Discovery Services
Lantern Pharma, a biotech leveraging A.I. and machine learning, has selected REPROCELL Inc. to provide drug screening and drug sensitivity services.
Mar 12, 2019
REPROCELL join Medicines Discovery Catapult’s Virtual R&D network to accelerate drug development
REPROCELL has joined Medicines Discovery Catapult’s Virtual R&D platform – a unique national network of consultants, private sector CROs, expert labs and public sector centres of excellence, providing medicines discovery expertise, services and virtual programme management.
Oct 10, 2018
ROSLINCT and REPROCELL awarded £1.2 million from Innovate UK for clinical-grade stem cell production
Learn more about the partnership between REPROCELL and ROSLINCT aiming to improve efficiency of induced pluripotent stem cell production
Apr 18, 2018
REPROCELL’s Dr David Bunton on April 2018 Trade Mission to China with Scottish First Minister Nicola Sturgeon
REPROCELL Europe’s CEO, Dr David Bunton, was part of the trade mission to China undertaken by the Scottish First Minister, the Rt. Hon. Nicola Sturgeon MSP, 9-13 April 2018.
Apr 06, 2018
Derek Mackay, SNP Cabinet Secretary for Finance and the Constitution, visits REPROCELL Europe, Glasgow
Read about REPROCELL's visit from Derek Mackay, the Scottish National Party’s Cabinet Secretary for Finance and the Constitution, on 05 April 2017
Mar 21, 2018
REPROCELL’s David Bunton addresses the Scottish Parliament
Discussing how sectors, such as life science, are affected by Scotland’s economic performance and what actions are required to make the economy more inclusive, innovative and international. Topics include key factors in company success, SME’s and government partnership.
Mar 14, 2018
Patient-derived tumor organoids recapitulate clinical treatments
REPROCELL is currently working to develop a highly predictive three-dimensional (3D) human micro-intestine model that can be used to test new drugs for the treatment of IBD and gastrointestinal cancers.
Nov 08, 2017
REPROCELL Chooses Science Exchange as the Preferred Partner to Increase Accessibility of its Predictive Drug Discovery Services
PALO ALTO, CA, November 8, 2017 – Science Exchange, the world’s leading and most secure enterprise platform for outsourced research services and procurement of human biospecimens, announced today that REPROCELL has selected the Science Exchange platform.
Sep 27, 2017
Article by Dr David Bunton (co-authored) in the European Pharmaceutical Review, Autumn 2017
REPROCELL Europe Ltd’s CEO, Dr David Bunton, has co-authored an article titled New Strategy that has been published in the European Pharmaceutical Review, Autumn 2017.
Aug 10, 2017
Nicola Sturgeon: interview at the official opening of REPROCELL’s Centre for Predictive Drug Discovery (YouTube video)
Video: First Minister Nicola Sturgeon officially opened the new European headquarters of a life sciences company which is set to generate 15 new jobs and safeguard a further three following new investment.
Aug 10, 2017
Press Release: Nicola Sturgeon, First Minister of Scotland, opens REPROCELL European Headquarters in Glasgow
REPROCELL Europe Ltd (REPROCELL), a leading provider of products and services for research in stem cells, drug discovery, human tissues and 3D cell culture and a member of the REPROCELL Group, has opened its European headquarters in Glasgow, UK.
Mar 03, 2017
REPROCELL Europe’s CEO Dr David Bunton presented at NC3Rs workshop: Human tissue models for cancer research
REPROCELL Europe’s CEO, Dr David Bunton presented at the recent NC3Rs meeting on the use of human tissues in cancer research. The conference considered the potential for human tissue models to help reduce clinical drug attrition and provide more relevant models of cancer
Feb 14, 2017
REPROCELL Inc CEO meets with Scottish Cabinet Secretary Fiona Hyslop in Japan
Read about the REPROCELL CEO's meeting with Fiona Hyslop, Cabinet Secretary for Culture, Tourism and External Affairs for the Scottish Government
Feb 07, 2017
Scottish Enterprise Association Honours REPROCELL with Annual Awards Nomination
Read about REPROCELL CEO Dr David Bunton's nomination for the Scottish Enterprise Association Life Science Business Leadership Award
Nov 11, 2016
Announcement on the initiation of a new business from the collaboration and commercialization agreement with Steminent Biotherapeutics Inc. for cell therapy
Read about REPROCELL's partnership with Steminent Biotherapeutics to develop and commercialize Steminent’s allogeneic stem cell therapy product Stemchymal.
May 13, 2016
Latest Proteon and Biopta publication demonstrates Proteon's Vonapanitase effects in human cephalic veins
Proteon Therapeutics Announces Publication in Cardiovascular Pharmacology: Open Access Describing Promising Nonclinical Results for Vonapanitase in Improving Arteriovenous Fistula (AVF) Maturation and patency in Chronic Kidney Disease (CKD) Patients.
Apr 21, 2016
Proteon and Biopta publication shows promising nonclinical results on Proteon's Vonapanitase
Proteon Therapeutics Announces Publication in the Journal of Cardiovascular Pharmacology of Promising Nonclinical Results for Vonapanitase in Peripheral Artery Disease.
Nov 25, 2015
REPROCELL acquires Biopta to expand its drug discovery services
The Japanese regenerative medicine company REPROCELL Inc. has announced the acquisition of the Scottish life sciences company, Biopta.
Nov 18, 2015
Biopta co-authors research in the European Respiratory Journal
The impact of fresh human tissue studies for translational work performed at Biopta has once again been demonstrated with this latest publication at the European Respiratory Society.
Oct 19, 2015
REPROCELL announces publication of a research report on “3D Skin Model Construction,” submitted to the International Scientific Journal “Molecular Cancer Therapeutics” by REPROCELL and others
Read more about REPROCELL CSO Professor Stefan Przyborski's latest publication on 3D Skin Model Construction published in Molecular Cancer Therapeutics